Investigational drug · Phase 3
BDB-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for ANCA Associated Vasculitis (AAV), ANCA-associated Vasculitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
13
Any phase or sponsor naming "BDB-001"
First trial start
2022
Feb 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BDB-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- ANCA Associated Vasculitis (AAV)
- ANCA-associated Vasculitis
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "BDB-001" as an intervention, largest first.
- Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDSPivotal-lookingTerminated
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT04449588 · 369 participants · Start Jul 23, 2020 · Primary completion Mar 26, 2024
Drug: BDB-001 Injection · For: COVID-19 Pneumonia
Sites: Dhaka, Bangladesh; Chongqing, China; Nagpur, India · 12 sites in all
- BDB-001 Phase III Trial in ANCA-Associated VasculitisPivotal-lookingRecruiting
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT07168161 · 300 participants (planned) · Start Nov 10, 2025 · Primary completion Apr 16, 2027
Drug: BDB-001 injection; Cyclophosphamide and 3 more · For: ANCA Associated Vasculitis (AAV)
Sites: Beijing, China; Chongqing, China; Xiamen, China · 65 sites in all
- Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid TumorsActive, not recruiting
Institut BergoniéAcademic, hospital or other
NCT03915678 · 247 participants (planned) · Start Mar 31, 2021 · Primary completion Dec 2026
Drug: Association atezolizumab + BDB001 + RT; Association atezolizumab + BDB001+ RT and 4 more · For: Solid Tumor, Adult; Pancreatic Cancer; Virus-associated Tumors and 4 more
Sites: Bordeaux, France; Brest, France; Caen, France · 11 sites in all
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05197842 · 93 participants · Start Feb 22, 2022 · Primary completion Mar 19, 2025
Drug: BDB-001 injection; Cyclophosphamide and 1 more · For: ANCA-associated Vasculitis
Sites: Hefei, China; Beijing, China; Nanning, China · 22 sites in all
- BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With PembrolizumabCompleted
Eikon TherapeuticsIndustry
NCT03486301 · 87 participants · Start Feb 15, 2018 · Primary completion Mar 31, 2024
Drug: BDB001 (EIK1001); Pembrolizumab · For: Tumor, Solid
Sites: Sarasota, Florida; Morristown, New Jersey; Nashville, Tennessee · 5 sites in all
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05103423 · 50 participants · Start Jun 24, 2021 · Primary completion Jul 7, 2023
Drug: BDB-001 Injection; Placebo and 1 more · For: Hidradenitis Suppurativa
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 15 sites in all
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05093855 · 41 participants · Start Aug 18, 2021 · Primary completion Aug 22, 2023
Drug: BDB-001 Injection · For: Hidradenitis Suppurativa
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 15 sites in all
Eikon TherapeuticsIndustry
NCT04196530 · 40 participants · Start Nov 21, 2019 · Primary completion Jul 31, 2024
Drug: BDB001 (EIK1001); Atezolizumab · For: Tumor, Solid
Sites: Los Angeles, California; Sarasota, Florida; Nashville, Tennessee · 5 sites in all
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05361005 · 33 participants · Start Mar 12, 2020 · Primary completion May 8, 2020
Drug: BDB-001 injection; Placebo · For: Healthy
Sites: Hangzhou, China
Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
NCT05360927 · 28 participants · Start Sep 25, 2019 · Primary completion Dec 25, 2020
Drug: BDB-001 injection; Placebo · For: Healthy
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
Also in development for ANCA Associated Vasculitis (AAV)
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.